Abbvie Inc. Common Stock (ABBV) 53.97 $ABBV
AbbVie Presents Results from Large Global Study of Patient Attitudes and Adherence Across Six Chronic Inflammatory Diseases
PR Newswire - Wed Jun 11, 1:00AM CDT
AbbVie (NYSE:ABBV) today announced results from its multi-country ALIGN study, which shows that across six chronic immune-mediated inflammatory diseases (IMIDs), adherence to treatment was generally higher in patients being treated with TNF inhibitors compared to patients treated with conventional therapy. Furthermore, patients who were "accepting" toward their medication were more often adherent, compared to patients who were "ambivalent" toward their medication, as estimated from their responses to validated questionnaires. Results were presented today at the European League Against Rheumatism (EULAR) 2014 Congress in Paris.
AbbVie Announces Michael Severino, M.D. to Lead R&D Organization and Drive Continued Pipeline Advancement
PR Newswire Europe - Tue Jun 10, 11:46PM CDT
-- New Chief Scientific Officer Brings Wealth of Experience in Biotech and Key Therapeutic Areas
Will Merck's Bold Hepatitis C Play Pay Off?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Tue Jun 10, 1:30PM CDT
There is a significant (and sometimes larger than expected) gap between "looks like it can compete" and actually competing with a rival that has both strong data and a big head start, but Merck continues to show that it is serious...
Idenix Skyrockets on Merck Acquisition Deal, Focus on HCV - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 10, 12:10PM CDT
Merck's (MRK) decision to acquire Idenix (IDIX) for $24.50 per share in cash will boost its hepatitis C virus (HCV) pipeline.
Up 58%: Should You Buy Achillion Pharmaceuticals Today?
Michael Douglass and Matt Trogdon, The Motley Fool - Motley Fool - Tue Jun 10, 10:09AM CDT
Investors in Achillion Pharmaceuticals got a double-whammy of good news over the last two days, with Merck 's purchase of fellow hepatitis c biotech Idenix pumping shares up over 40%. And Achillion is up over 50% today on further good news --...
AbbVie to Present at Goldman Sachs 35th Annual Global Healthcare Conference
PR Newswire - Tue Jun 10, 7:00AM CDT
AbbVie (NYSE: ABBV) will participate in the Goldman Sachs 35th Annual Global Healthcare Conference on Wednesday, June 11, 2014. Bill Chase, executive vice president and chief financial officer, will take part in a question and answer session at 10:40 a.m. Central time.
Here's Why Merck Paid Triple the Price for Idenix
Alex Dumortier, CFA, The Motley Fool - Motley Fool - Mon Jun 09, 6:15PM CDT
U.S. stocks put in another record high on Monday -- the ninth in 11 trading sessions -- as the benchmark S&P 500 and the narrower Dow Jones Industrial Average both rose 0.1%. The technology-heavy Nasdaq Composite Index gained 0.4%. ...
Idiopathic Juvenile Arthritis (Still's Disease) - Pipeline Review, H1 2014
M2 - Mon Jun 09, 10:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zrx5qq/idiopathic) has announced the addition of the "Idiopathic Juvenile Arthritis (Still's Disease) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Idiopathic Juvenile Arthritis (Still's Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Idiopathic Juvenile Arthritis (Still's Disease) and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - Celltrion, Inc. - Biocon Limited - Pfizer Inc. - UCB S.A. - Sandoz Inc. - Swedish Orphan Biovitrum AB - Biosidus S.A. - Genor BioPharma Co., Ltd. - AbbVie Inc. - Epirus Biopharmaceuticals, Inc. - AlphaMab Co., Ltd For more information visit http://www.researchandmarkets.com/research/zrx5qq/idiopathic
Achillion Pharma Might be Next Hep C Takeout Target
at The Street - Mon Jun 09, 8:22AM CDT
Johnson & Johnson and Abbvie were both reportedly interesting in buying Idenix but lost out to Merck, reports CNBC. Achillion shares are up almost 30% to $TK Monday as investors bet the losers in the Idenix sweepstakes may move on to the next target.
Merck Buys Idenix for $3.9B in Yet Another Blockbuster Hep C Deal
at The Street - Mon Jun 09, 7:27AM CDT
With Gilead Sciences already marketing the hepatitis C pill Sovaldi and competition from Abbvie-Enanta Pharma and Bristol-Myers Squibb close behind, a lot of investors believed the hepatitis C drug race had transitioned to marketing and away from...
The Repercussions of Medicare's New Hepatitis C Push
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Sun Jun 08, 12:31PM CDT
This week, the Centers for Medicare & Medicaid Services, or CMS, announced a big shift in health policy. CMS intends to cover screening for hepatitis C for members who fall into either of two buckets: those who are considered to be at high risk...
Biotech Stock Roundup: Gilead, Pharmacyclics Impress at ASCO - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jun 04, 11:14AM CDT
It was ASCO all the way with several biotech companies presenting data at the highly-awaited annual meeting.
ASCO 2014 Puts These Biotech Stocks in Focus - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Jun 03, 10:10AM CDT
Companies like Amgen (AMGN), Gilead (GILD), Pharmacyclics (PCYC) were out in full force presenting data on their approved and experimental cancer drugs.
Life After Pfizer: AstraZeneca Hopes for Oncology Success
Todd Campbell, The Motley Fool - Motley Fool - Tue Jun 03, 8:00AM CDT
European and U.S. regulators this year are considering approval for AstraZeneca 's Olaparib, a drug designed to treat ovarian cancer patients with a specific mutation to the BRCA gene. Approval could have an impact on a variety of other...
AbbVie to Present at Jefferies 2014 Global Healthcare Conference
PR Newswire - Tue Jun 03, 7:30AM CDT
AbbVie (NYSE: ABBV) will participate in the Jefferies 2014 Global Healthcare Conference on Wednesday, June 4, 2014. Scott Brun, M.D., vice president, pharmaceutical development, will take part in a question and answer session at 8:30 a.m. Central time.
Merck Presents Positive Trial Results For Cancer Drug
at Investor's Business Daily - Mon Jun 02, 4:12PM CDT
Merck (MRK) seeks to add potential new blockbuster drugs to its disease-fighting arsenal as it takes on cancer and hepatitis C. On Monday, the drugmaker presented results from a phase-one trial of its pembrolizumab cancer treatment at the American...
Roche Acquires Genia Technologies - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 02, 3:40PM CDT
In a bid to strengthen its diagnostics portfolio, Roche (RHHBY) announced that it will acquire privately held Genia Technologies for $125 million in cash. Roche will also make milestone payments of $225 million upon achievement
AbbVie Presents New Results from Studies of Investigational Oncology Compound ABT-199/GDC-0199 at the 2014 American Society of Clinical Oncology Annual Meeting
PR Newswire - Sat May 31, 7:00AM CDT
AbbVie (NYSE: ABBV) released interim results from a Phase Ib clinical trial of ABT-199/GDC-0199, an investigational B-cell lymphoma 2 (BCL-2) selective inhibitor, in combination with rituximab (Abstract 7013). Results showed an overall response rate (ORR) of 84 percent, in patients with relapsed/refractory chronic lymphocytic leukemia (CLL), the most common leukemia in the United States. These results were presented at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), May 30 - June 3 in Chicago.
Pharmacyclics' Imbruvica Extends Survival in Elderly Leukemia Patients
at The Street - Sat May 31, 6:35AM CDT
Pharmacyclics and Johnson & Johnson's blood-cancer drug Imbruvica reduced the risk of dying by 57% compared to GlaxoSmithKline's Arzerra when used to treat elderly patients with relapsed chronic lymphocytic leukemia, according to results from a phase...
3 Reasons Why Wall Street Hates Idenix Pharmaceuticals, Inc.
George Budwell, The Motley Fool - Motley Fool - Fri May 30, 5:30PM CDT
After getting routed the last two years, short sellers finally had their day in biotech in the first-quarter of this year. Although many small-cap biotechs plunged by double-digits during this period, we are now starting to see signs that the worst...
AbbVie Presents Results from Large Global Study of Patient Attitudes and Adherence Across Six Chronic Inflammatory Diseases
PR Newswire - Wed Jun 11, 1:00AM CDT
AbbVie (NYSE:ABBV) today announced results from its multi-country ALIGN study, which shows that across six chronic immune-mediated inflammatory diseases (IMIDs), adherence to treatment was generally higher in patients being treated with TNF inhibitors compared to patients treated with conventional therapy. Furthermore, patients who were "accepting" toward their medication were more often adherent, compared to patients who were "ambivalent" toward their medication, as estimated from their responses to validated questionnaires. Results were presented today at the European League Against Rheumatism (EULAR) 2014 Congress in Paris.
AbbVie Announces Michael Severino, M.D. to Lead R&D Organization and Drive Continued Pipeline Advancement
PR Newswire Europe - Tue Jun 10, 11:46PM CDT
-- New Chief Scientific Officer Brings Wealth of Experience in Biotech and Key Therapeutic Areas
Will Merck's Bold Hepatitis C Play Pay Off?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Tue Jun 10, 1:30PM CDT
There is a significant (and sometimes larger than expected) gap between "looks like it can compete" and actually competing with a rival that has both strong data and a big head start, but Merck continues to show that it is serious...
Idenix Skyrockets on Merck Acquisition Deal, Focus on HCV - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 10, 12:10PM CDT
Merck's (MRK) decision to acquire Idenix (IDIX) for $24.50 per share in cash will boost its hepatitis C virus (HCV) pipeline.
Up 58%: Should You Buy Achillion Pharmaceuticals Today?
Michael Douglass and Matt Trogdon, The Motley Fool - Motley Fool - Tue Jun 10, 10:09AM CDT
Investors in Achillion Pharmaceuticals got a double-whammy of good news over the last two days, with Merck 's purchase of fellow hepatitis c biotech Idenix pumping shares up over 40%. And Achillion is up over 50% today on further good news --...
AbbVie to Present at Goldman Sachs 35th Annual Global Healthcare Conference
PR Newswire - Tue Jun 10, 7:00AM CDT
AbbVie (NYSE: ABBV) will participate in the Goldman Sachs 35th Annual Global Healthcare Conference on Wednesday, June 11, 2014. Bill Chase, executive vice president and chief financial officer, will take part in a question and answer session at 10:40 a.m. Central time.
Here's Why Merck Paid Triple the Price for Idenix
Alex Dumortier, CFA, The Motley Fool - Motley Fool - Mon Jun 09, 6:15PM CDT
U.S. stocks put in another record high on Monday -- the ninth in 11 trading sessions -- as the benchmark S&P 500 and the narrower Dow Jones Industrial Average both rose 0.1%. The technology-heavy Nasdaq Composite Index gained 0.4%. ...
Idiopathic Juvenile Arthritis (Still's Disease) - Pipeline Review, H1 2014
M2 - Mon Jun 09, 10:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zrx5qq/idiopathic) has announced the addition of the "Idiopathic Juvenile Arthritis (Still's Disease) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Idiopathic Juvenile Arthritis (Still's Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Idiopathic Juvenile Arthritis (Still's Disease) and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - Celltrion, Inc. - Biocon Limited - Pfizer Inc. - UCB S.A. - Sandoz Inc. - Swedish Orphan Biovitrum AB - Biosidus S.A. - Genor BioPharma Co., Ltd. - AbbVie Inc. - Epirus Biopharmaceuticals, Inc. - AlphaMab Co., Ltd For more information visit http://www.researchandmarkets.com/research/zrx5qq/idiopathic
Achillion Pharma Might be Next Hep C Takeout Target
at The Street - Mon Jun 09, 8:22AM CDT
Johnson & Johnson and Abbvie were both reportedly interesting in buying Idenix but lost out to Merck, reports CNBC. Achillion shares are up almost 30% to $TK Monday as investors bet the losers in the Idenix sweepstakes may move on to the next target.
Merck Buys Idenix for $3.9B in Yet Another Blockbuster Hep C Deal
at The Street - Mon Jun 09, 7:27AM CDT
With Gilead Sciences already marketing the hepatitis C pill Sovaldi and competition from Abbvie-Enanta Pharma and Bristol-Myers Squibb close behind, a lot of investors believed the hepatitis C drug race had transitioned to marketing and away from...
The Repercussions of Medicare's New Hepatitis C Push
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Sun Jun 08, 12:31PM CDT
This week, the Centers for Medicare & Medicaid Services, or CMS, announced a big shift in health policy. CMS intends to cover screening for hepatitis C for members who fall into either of two buckets: those who are considered to be at high risk...
Biotech Stock Roundup: Gilead, Pharmacyclics Impress at ASCO - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jun 04, 11:14AM CDT
It was ASCO all the way with several biotech companies presenting data at the highly-awaited annual meeting.
ASCO 2014 Puts These Biotech Stocks in Focus - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Jun 03, 10:10AM CDT
Companies like Amgen (AMGN), Gilead (GILD), Pharmacyclics (PCYC) were out in full force presenting data on their approved and experimental cancer drugs.
Life After Pfizer: AstraZeneca Hopes for Oncology Success
Todd Campbell, The Motley Fool - Motley Fool - Tue Jun 03, 8:00AM CDT
European and U.S. regulators this year are considering approval for AstraZeneca 's Olaparib, a drug designed to treat ovarian cancer patients with a specific mutation to the BRCA gene. Approval could have an impact on a variety of other...
AbbVie to Present at Jefferies 2014 Global Healthcare Conference
PR Newswire - Tue Jun 03, 7:30AM CDT
AbbVie (NYSE: ABBV) will participate in the Jefferies 2014 Global Healthcare Conference on Wednesday, June 4, 2014. Scott Brun, M.D., vice president, pharmaceutical development, will take part in a question and answer session at 8:30 a.m. Central time.
Merck Presents Positive Trial Results For Cancer Drug
at Investor's Business Daily - Mon Jun 02, 4:12PM CDT
Merck (MRK) seeks to add potential new blockbuster drugs to its disease-fighting arsenal as it takes on cancer and hepatitis C. On Monday, the drugmaker presented results from a phase-one trial of its pembrolizumab cancer treatment at the American...
Roche Acquires Genia Technologies - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 02, 3:40PM CDT
In a bid to strengthen its diagnostics portfolio, Roche (RHHBY) announced that it will acquire privately held Genia Technologies for $125 million in cash. Roche will also make milestone payments of $225 million upon achievement
AbbVie Presents New Results from Studies of Investigational Oncology Compound ABT-199/GDC-0199 at the 2014 American Society of Clinical Oncology Annual Meeting
PR Newswire - Sat May 31, 7:00AM CDT
AbbVie (NYSE: ABBV) released interim results from a Phase Ib clinical trial of ABT-199/GDC-0199, an investigational B-cell lymphoma 2 (BCL-2) selective inhibitor, in combination with rituximab (Abstract 7013). Results showed an overall response rate (ORR) of 84 percent, in patients with relapsed/refractory chronic lymphocytic leukemia (CLL), the most common leukemia in the United States. These results were presented at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), May 30 - June 3 in Chicago.
Pharmacyclics' Imbruvica Extends Survival in Elderly Leukemia Patients
at The Street - Sat May 31, 6:35AM CDT
Pharmacyclics and Johnson & Johnson's blood-cancer drug Imbruvica reduced the risk of dying by 57% compared to GlaxoSmithKline's Arzerra when used to treat elderly patients with relapsed chronic lymphocytic leukemia, according to results from a phase...
3 Reasons Why Wall Street Hates Idenix Pharmaceuticals, Inc.
George Budwell, The Motley Fool - Motley Fool - Fri May 30, 5:30PM CDT
After getting routed the last two years, short sellers finally had their day in biotech in the first-quarter of this year. Although many small-cap biotechs plunged by double-digits during this period, we are now starting to see signs that the worst...
